JP2016533392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533392A5 JP2016533392A5 JP2016545265A JP2016545265A JP2016533392A5 JP 2016533392 A5 JP2016533392 A5 JP 2016533392A5 JP 2016545265 A JP2016545265 A JP 2016545265A JP 2016545265 A JP2016545265 A JP 2016545265A JP 2016533392 A5 JP2016533392 A5 JP 2016533392A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- lys
- arg
- ald
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 206010012239 Delusion Diseases 0.000 claims 6
- 230000001149 cognitive effect Effects 0.000 claims 6
- 231100000868 delusion Toxicity 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 206010027951 Mood swings Diseases 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 230000016571 aggressive behavior Effects 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 230000035807 sensation Effects 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 230000001755 vocal effect Effects 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 102000004020 Oxygenases Human genes 0.000 claims 1
- 108090000417 Oxygenases Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884722P | 2013-09-30 | 2013-09-30 | |
| US61/884,722 | 2013-09-30 | ||
| PCT/US2014/058049 WO2015048647A1 (en) | 2013-09-30 | 2014-09-29 | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Division JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533392A JP2016533392A (ja) | 2016-10-27 |
| JP2016533392A5 true JP2016533392A5 (https=) | 2017-11-09 |
| JP6434523B2 JP6434523B2 (ja) | 2018-12-05 |
Family
ID=52744565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545265A Expired - Fee Related JP6434523B2 (ja) | 2013-09-30 | 2014-09-29 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210325A Withdrawn JP2019052158A (ja) | 2013-09-30 | 2018-11-08 | カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160375088A1 (https=) |
| EP (1) | EP3052115A4 (https=) |
| JP (2) | JP6434523B2 (https=) |
| CN (1) | CN106163537A (https=) |
| AU (2) | AU2014324580B2 (https=) |
| CA (1) | CA2925757A1 (https=) |
| WO (1) | WO2015048647A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
| US20170007663A1 (en) * | 2013-12-16 | 2017-01-12 | Cornell University | Methods and compositions for treating and preventing cognitive dysfunction |
| WO2017180535A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN107320711A (zh) * | 2017-03-24 | 2017-11-07 | 南京大学 | 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用 |
| CN114269768A (zh) * | 2019-10-16 | 2022-04-01 | 纳特恩斯株式会社 | 用于改善记忆力和预防或改善认知功能障碍的肽及包含该肽的组合物、及其制备方法 |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382095A1 (en) * | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| EP1599216B9 (en) * | 2003-02-04 | 2015-02-11 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| CA3024434A1 (en) * | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CN104788540B (zh) * | 2005-09-16 | 2019-10-18 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
| CA2839408A1 (en) * | 2011-06-14 | 2012-12-20 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| EP3052115A4 (en) * | 2013-09-30 | 2017-09-27 | Cornell University | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
-
2014
- 2014-09-29 EP EP14848640.0A patent/EP3052115A4/en not_active Withdrawn
- 2014-09-29 CA CA2925757A patent/CA2925757A1/en not_active Abandoned
- 2014-09-29 AU AU2014324580A patent/AU2014324580B2/en not_active Ceased
- 2014-09-29 JP JP2016545265A patent/JP6434523B2/ja not_active Expired - Fee Related
- 2014-09-29 US US15/025,612 patent/US20160375088A1/en not_active Abandoned
- 2014-09-29 WO PCT/US2014/058049 patent/WO2015048647A1/en not_active Ceased
- 2014-09-29 CN CN201480063400.5A patent/CN106163537A/zh active Pending
-
2018
- 2018-11-08 JP JP2018210325A patent/JP2019052158A/ja not_active Withdrawn
-
2020
- 2020-05-25 AU AU2020203424A patent/AU2020203424A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533392A5 (https=) | ||
| ES2337700T3 (es) | Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño. | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| ES2663680T3 (es) | Composiciones que comprenden vortioxetina y donepezilo | |
| JP2019532926A5 (https=) | ||
| NZ594184A (en) | Skin treatment | |
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| JP2017535612A5 (https=) | ||
| PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2007505139A5 (https=) | ||
| JP2013533287A5 (https=) | ||
| JP2014050390A5 (https=) | ||
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| RU2007125589A (ru) | Способ улучшения структуры и/или функций артериол, активный агент для улучшения структуры и/или функций артериол и набор для лечения состояний, характеризующихся ненормальной структурой или функцией артериол | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2008110970A5 (https=) | ||
| JP2018521086A5 (https=) | ||
| JP2016533346A5 (https=) | ||
| JP2013543004A5 (https=) | ||
| JP2018505218A5 (https=) | ||
| CN102266312A (zh) | 替普瑞酮在制备预防和/或治疗阿片类毒品成瘾药物中的应用 | |
| JP2009500045A5 (https=) |